Basics NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. IPO Date: September 28, 2015 Sector: Healthcare Industry: Medical Instruments and Supplies Market Cap: $2.14B Activated in VL: True Average Daily Range Avg Daily Range: $1.35 | 2.70% Avg Daily Range (30 D): $0.36 | 2.04% Avg Daily Range (90 D): $0.46 | 2.40% Institutional Daily Volume Avg Daily Volume: .76M Avg Daily Volume (30 D): .74M Avg Daily Volume (90 D): .7M Trade Size Avg Trade Size (Sh.): 72 Avg Trade Size (Sh.) (30 D): 58 Avg Trade Size (Sh.) (90 D): 53 Institutional Trades Total Inst.Trades: 4,880 Avg Inst. Trade: $3.63M Avg Inst. Trade (30 D): $1.99M Avg Inst. Trade (90 D): $2.34M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.6M Avg Closing Trade (30 D): $2.25M Avg Closing Trade (90 D): $2.67M Avg Closing Volume: 103.73K         News Apr 24, 2025 @ 1:25 PM NovoCure Surpasses Q1 Expectations Source: Jesterai Apr 16, 2025 @ 7:43 PM Why NovoCure Stock Was Withering on Wednesday Source: Eric Volkman Dec 6, 2024 @ 1:32 PM Why NovoCure Stock Was Winning Big This Week Source: Eric Volkman Sep 6, 2024 @ 9:19 PM Why NovoCure Stock Dived by 13% This Week Source: Eric Volkman Jun 4, 2024 @ 1:01 PM A Closer Look at 7 Analyst Recommendations For Nov... Source: Benzinga Insights Financials   TTM Q1 2025 Q3 2024 Basic EPS $-1.51 $-.31 $-.28 Diluted EPS $-1.51 $-.31 $-.28 Revenue $ 621.71M $ 154.99M $ 155.1M Gross Profit $ 479.7M $ 116.47M $ 119.72M Net Income / Loss $ -164.19M $ -34.32M $ -30.57M Operating Income / Loss $ -166.84M $ -37.87M $ -32.09M Cost of Revenue $ 142.01M $ 38.52M $ 35.37M Net Cash Flow $ -327.93M $ -36.66M $ 20.76M PE Ratio